Figure 2.

BmooMPα-I activates COX-1 and COX-2 pathways to release PGE₂ and upregulates COX-2 protein expression: (A) cultured preadipocytes were pretreated with the selective inhibitors of COX-1, COX-2, SC-560, and NS-398 for 1 h and incubated with BmooMPα-I (0.24 μM) or DMEM (control) for 12 h, then supernatants were collected and PGE₂ was quantified by ELISA; (B–E) preadipocytes were incubated with BmooMPα-I (0.24 µM) (Bmoo) or DMEM (control) for 1, 3, 6, 12, and 24 h; (B) representative Western blotting of COX-1 and β-actin (loading control) showing immunoreactive bands; (D) representative Western blotting of COX-2 and β-actin (loading control) showing immunoreactive bands; densitometric analysis of immunoreactive (C) COX-1 and (E) COX-2 bands. Data are means ± SEM of 4 samples. Note: * p < 0.05 relative to control; ^# p < 0.05 relative to BmooMPα-I (with vehicle); (A) one-way ANOVA and Bonferroni post-test; (C,E) two-way ANOVA and Bonferroni post-test.